Daniel Lindner, M.D., Ph.D.
| Appointed: |
1999 |
| Gender: |
Male |
| Languages: |
English |
Translational Hematology and Oncology Research
Cancer Biology
Associate Medical Director
Biographical Sketch
Daniel J. Lindner, MD, PhD, is an Associate Staff at the Taussig Cancer Institute in the Center for Hematology and Oncology Molecular Therapeutics, and in the Lerner Research Institute, Cleveland Clinic (Department of Cancer Biology), and also Assistant Professor at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University (Molecular Medicine). He is investigating the role of inositol kinases in apoptosis and developing experimental therapeutics for cancer based on cobalamins and nitric oxide.
Dr. Lindner received his BS degree from Massachusetts Institute of Technology in 1977, his MD from Georgetown University in 1981, and his PhD in microbiology from the Medical College of Wisconsin in 1996. His postdoctoral training was at the Greenebaum Cancer Center at the University of Maryland. He joined Cleveland Clinic in 1999.
In the past five years he has attracted over $2 million in funding from NIH/NCI. In 2002, he founded the Animal Tumor Core. Under his direction, the Tumor Core performs xenograft and syngeneic tumor studies for principal investigators of Cleveland Clinic and Case Western Reserve University. At age 52, Dr. Lindner has 59 publications and two U.S. patents.
Education & Fellowships
| Medical School: | Georgetown University, Washington, DC |
|
| Internship: | Oregon Health Sciences University Hospital, Surgery, Portland, OR |
| Residency: | Oregon Health Sciences University Hospital, General Surgery, Portland, OR |
| Residency: | Oregon Health Sciences University Hospital, Research in Vascular Surgery, Portland, OR |
| Residency: | Oregon Health Sciences University Hospital, Surgery, Portland, OR |
| Other Education: | (Doctorate) Medical College of Wisconsin, Milwaukee, WI |
| Other Education: | (Undergraduate) Massachusetts Institute of Technology, Cambridge, MA |
Specialty Interests
Drug Discovery.
Innovations & Patents
- U.S. Patent Pending; Bauer J.A and Lindner DJ: Composition and methods for inhibiting cell survival, 2002
- U.S. Patent # 6,752,986; Bauer JA and Lindner DJ: Composition and methods for affecting metallocorrinoid uptake, 2001
- (Both patents relate to nitrosylcobalamin, a pro-drug synthesized from nitric oxide and vitamin B12)
Industry Relationships
Cleveland Clinic physicians and scientists report if they have any collaborations with the pharmaceutical or medical device industries as part of the Cleveland Clinic’s procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its doctors’ connections with industry and those of their immediate family members. As of 8/28/2008, Dr. Lindner has reported no financial relationship with industry that is applicable to this listing. Patients should feel free to contact their doctor about relationships with industry and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic’s policies on collaborations with industry and innovation management, go to our
Integrity in Innovation page.
( † Disclaimer: This search is powered by PubMed, a service of the U.S.
National Library of Medicine. PubMed is a third-party website with no
affiliation with Cleveland Clinic.)
